FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lask Alisa		 2. Issuer Name and Ticker or Trading Symbol

NEPHROS INC [ NEPH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O NEPHROS, INC., 380 LACKAWANNA PLACE		 3. Date of Earliest Transaction (MM/DD/YYYY)

1/5/2023
(Street)

SOUTH ORANGE, NJ 07079
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/5/2023  A  27613 (1)A$0 39338 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $5.2200            (2)2/8/2029 Common Stock 9617  9617 D  
Stock Option (right to buy) $8.5700            (2)12/16/2029 Common Stock 5568  5568 D  
Stock Option (right to buy) $8.0600            (2)1/6/2031 Common Stock 6850  6850 D  
Stock Option (right to buy) $6.82            (3)12/14/2031 Common Stock 7062  7062 D  
Stock Option (right to buy) $1.07 1/5/2023  A   7080     (4)1/5/2033 Common Stock 7080 $0 7080 D  
Explanation of Responses:
(1) Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.
(2) Fully exercisable.
(3) This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23.
(4) Represents options granted to the reporting person for her service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lask Alisa
C/O NEPHROS, INC.
380 LACKAWANNA PLACE
SOUTH ORANGE, NJ 07079		X
Signatures
/s/ Christopher Melsha as attorney-in-fact for Alisa Lask pursuant to power of attorney previously filed.1/9/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nephros (NASDAQ:NEPH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024 Click aqui para mais gráficos Nephros.
Nephros (NASDAQ:NEPH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024 Click aqui para mais gráficos Nephros.